Vertex: A Jewel In The Biotech Space


After the strong Phase II data for the triple combo, I'm looking for any sustained pullback in the name to build my position. Last week Vertex reported better-than-expected Q2/2017 results , driven by a solid performance for both Orkambi and Kalydeco.



from Biotech News